A2AR--STAT1 (Y701) -HLA-E轴作为放射治疗耐药三阴性乳腺癌中潜在的免疫调节途径

Young Shin Ko1,2, Hana Jin1, So Eun Lee1,2

  • 1Department of Pharmacology, College of Medicine, Institute of Medical Sciences, Gyeongsang National University, Jinjudaero 816 Bungil 15, Jinju 52727, Republic of Korea.

Carcinogenesis
|October 22, 2025
PubMed
概括

三阴性乳腺癌 (TNBC) 对放射治疗的耐药性与增加的HLA-E表达有关. 针对A2AR-STAT1通路,使用弗鲁达拉宾或莫纳利祖马布等药物,可以克服这种抗药性.

相关概念视频

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K